Truist Securities Maintains Buy on Inspire Medical Systems, Lowers Price Target to $340
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has maintained a 'Buy' rating on Inspire Medical Systems (NYSE:INSP) but lowered the price target from $363 to $340.
August 24, 2023 | 6:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Inspire Medical Systems' price target has been lowered by Truist Securities from $363 to $340, though the 'Buy' rating is maintained.
The lowering of the price target by Truist Securities could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100